Home LiteratureArticle Details
PMID: 29720655 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Molecular mechanism of GPCR-mediated arrestin activation.

Nature ·Vol. 557 ·No. 7705 ·2018-00-00 ·Pages 452-456

Latorraca NR, Wang JK, Bauer B, Townshend RJL, Hollingsworth SA, Olivieri JE, Xu HE, Sommer ME, Dror RO

Abstract

Despite intense interest in discovering drugs that cause G-protein-coupled receptors (GPCRs) to selectively stimulate or block arrestin signalling, the structural mechanism of receptor-mediated arrestin activation remains unclear1,2. Here we reveal this mechanism through extensive atomic-level simulations of arrestin. We find that the receptor's transmembrane core and cytoplasmic tail-which bind distinct surfaces on arrestin-can each independently stimulate arrestin activation. We confirm this unanticipated role of the receptor core, and the allosteric coupling between these distant surfaces of arrestin, using site-directed fluorescence spectroscopy. The effect of the receptor core on arrestin conformation is mediated primarily by interactions of the intracellular loops of the receptor with the arrestin body, rather than the marked finger-loop rearrangement that is observed upon receptor binding. In the absence of a receptor, arrestin frequently adopts active conformations when its own C-terminal tail is disengaged, which may explain why certain arrestins remain active long after receptor dissociation. Our results, which suggest that diverse receptor binding modes can activate arrestin, provide a structural foundation for the design of functionally selective ('biased') GPCR-targeted ligands with desired effects on arrestin signalling.

MeSH Terms
Animals Arrestins/chemistry,metabolism Cattle Ligands Receptors, G-Protein-Coupled/chemistry,metabolism Signal Transduction Spectrometry, Fluorescence
Chemicals
Arrestins Ligands Receptors, G-Protein-Coupled
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Latorraca Naomi R
Biophysics Program, Stanford University, Stanford, CA, USA. | Department of Computer Science, Stanford University, Stanford, CA, USA. | Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA. | Institute for Computational and Mathematical Engineering, Stanford University, Stanford, CA, USA.
Wang Jason K
Department of Computer Science, Stanford University, Stanford, CA, USA.
Bauer Brian
Institut für Medizinische Physik und Biophysik (CC2), Charité-Universitätsmedizin Berlin, Berlin, Germany.
Townshend Raphael J L
Department of Computer Science, Stanford University, Stanford, CA, USA.
Hollingsworth Scott A
Biophysics Program, Stanford University, Stanford, CA, USA. | Department of Computer Science, Stanford University, Stanford, CA, USA. | Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Olivieri Julia E
Institute for Computational and Mathematical Engineering, Stanford University, Stanford, CA, USA.
Xu H Eric
VARI-SIMM Center, Center for Structure and Function of Drug Targets, CAS-Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. | Laboratory of Structural Sciences, Center for Structural Biology and Drug Discovery, Van Andel Research Institute, Grand Rapids, MI, USA.
Sommer Martha E
Institut für Medizinische Physik und Biophysik (CC2), Charité-Universitätsmedizin Berlin, Berlin, Germany. martha.sommer@charite.de.
Dror Ron O
Biophysics Program, Stanford University, Stanford, CA, USA. ron.dror@stanford.edu. | Department of Computer Science, Stanford University, Stanford, CA, USA. ron.dror@stanford.edu. | Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA. ron.dror@stanford.edu. | Institute for Computational and Mathematical Engineering, Stanford University, Stanford, CA, USA. ron.dror@stanford.edu.
References (73)
73 references, click to expand
  1. How does arrestin respond to the phosphorylated state of rhodopsin?
    J Biol Chem. 1999 Apr 23;274(17):11451-4 PMID: 10206946
  2. The 2.8 A crystal structure of visual arrestin: a model for arrestin's regulation.
    Cell. 1999 Apr 16;97(2):257-69 PMID: 10219246
  3. Isolation of isoelectric species of phosphorylated rhodopsin.
    Methods Enzymol. 2000;315:70-6 PMID: 10736694
  4. High-performance liquid chromatography analysis of visual cycle retinoids.
    Methods Enzymol. 2000;316:313-24 PMID: 10800683
  5. An additional phosphate-binding element in arrestin molecule. Implications for the mechanism of arrestin activation.
    J Biol Chem. 2000 Dec 29;275(52):41049-57 PMID: 11024026
  6. Conformations of the active and inactive states of opsin.
    J Biol Chem. 2001 Oct 19;276(42):38487-93 PMID: 11502747
  7. Crystal structure of beta-arrestin at 1.9 A: possible mechanism of receptor binding and membrane Translocation.
    Structure. 2001 Sep;9(9):869-80 PMID: 11566136
  8. beta-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: identification of a beta-arrestin binging site in beta 2-adaptin.
    J Biol Chem. 2002 Mar 15;277(11):9247-54 PMID: 11777907
  9. Mapping proximity within proteins using fluorescence spectroscopy. A study of T4 lysozyme showing that tryptophan residues quench bimane fluorescence.
    Biochemistry. 2002 Feb 26;41(8):2475-84 PMID: 11851393
  10. Aspartic acid 564 in the third cytoplasmic loop of the luteinizing hormone/choriogonadotropin receptor is crucial for phosphorylation-independent interaction with arrestin2.
    J Biol Chem. 2002 May 17;277(20):17916-27 PMID: 11867621
  11. The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation.
    J Biol Chem. 2003 Feb 21;278(8):6258-67 PMID: 12473660
  12. Human substance P receptor lacking the C-terminal domain remains competent to desensitize and internalize.
    J Neurochem. 2003 Feb;84(4):854-63 PMID: 12562528
  13. Phosphorylation-independent beta-arrestin translocation and internalization of leukotriene B4 receptors.
    J Biol Chem. 2005 Feb 11;280(6):4880-7 PMID: 15561704
  14. Dynamics of arrestin-rhodopsin interactions: arrestin and retinal release are directly linked events.
    J Biol Chem. 2005 Feb 25;280(8):6861-71 PMID: 15591052
  15. The differential engagement of arrestin surface charges by the various functional forms of the receptor.
    J Biol Chem. 2006 Feb 10;281(6):3458-62 PMID: 16339758
  16. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors.
    Pharmacol Ther. 2006 Jun;110(3):465-502 PMID: 16460808
  17. Role of the carboxyl-terminal region of arrestin in binding to phosphorylated rhodopsin.
    J Biol Chem. 1991 Aug 15;266(23):15334-9 PMID: 1651326
  18. Targeted molecular dynamics study of C-loop closure and channel gating in nicotinic receptors.
    PLoS Comput Biol. 2006 Sep 29;2(9):e134 PMID: 17009865
  19. The active conformation of beta-arrestin1: direct evidence for the phosphate sensor in the N-domain and conformational differences in the active states of beta-arrestins1 and -2.
    J Biol Chem. 2007 Jul 20;282(29):21370-81 PMID: 17513300
  20. Dynamics of arrestin-rhodopsin interactions: loop movement is involved in arrestin activation and receptor binding.
    J Biol Chem. 2007 Aug 31;282(35):25560-8 PMID: 17606620
  21. G-protein-coupled receptor phosphorylation: where, when and by whom.
    Br J Pharmacol. 2008 Mar;153 Suppl 1:S167-76 PMID: 18193069
  22. A model for the solution structure of the rod arrestin tetramer.
    Structure. 2008 Jun;16(6):924-34 PMID: 18547524
  23. Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors.
    Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):9988-93 PMID: 18621717
  24. Two protonation switches control rhodopsin activation in membranes.
    Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17795-800 PMID: 18997017
  25. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields.
    J Comput Chem. 2010 Mar;31(4):671-90 PMID: 19575467
  26. Efficient nonbonded interactions for molecular dynamics on a graphics processing unit.
    J Comput Chem. 2010 Apr 30;31(6):1268-72 PMID: 19847780
  27. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types.
    J Phys Chem B. 2010 Jun 17;114(23):7830-43 PMID: 20496934
  28. Arrestin-rhodopsin binding stoichiometry in isolated rod outer segment membranes depends on the percentage of activated receptors.
    J Biol Chem. 2011 Mar 4;286(9):7359-69 PMID: 21169358
  29. How robust are protein folding simulations with respect to force field parameterization?
    Biophys J. 2011 May 4;100(9):L47-9 PMID: 21539772
  30. Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology.
    Circ Res. 2011 Jul 8;109(2):205-16 PMID: 21737816
  31. Role of receptor-attached phosphates in binding of visual and non-visual arrestins to G protein-coupled receptors.
    J Biol Chem. 2012 Mar 16;287(12):9028-40 PMID: 22275358
  32. Crystal structure of p44, a constitutively active splice variant of visual arrestin.
    J Mol Biol. 2012 Mar 9;416(5):611-8 PMID: 22306737
  33. Distinct loops in arrestin differentially regulate ligand binding within the GPCR opsin.
    Nat Commun. 2012;3:995 PMID: 22871814
  34. Inclusion of many-body effects in the additive CHARMM protein CMAP potential results in enhanced cooperativity of α-helix and β-hairpin formation.
    Biophys J. 2012 Sep 5;103(5):1045-51 PMID: 23009854
  35. Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges.
    J Chem Inf Model. 2012 Dec 21;52(12):3155-68 PMID: 23145473
  36. Automation of the CHARMM General Force Field (CGenFF) I: bond perception and atom typing.
    J Chem Inf Model. 2012 Dec 21;52(12):3144-54 PMID: 23146088
  37. OpenMM 4: A Reusable, Extensible, Hardware Independent Library for High Performance Molecular Simulation.
    J Chem Theory Comput. 2013 Jan 8;9(1):461-469 PMID: 23316124
  38. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles.
    J Chem Theory Comput. 2012 Sep 11;8(9):3257-3273 PMID: 23341755
  39. β-Arrestins and G protein-coupled receptor trafficking.
    Methods Enzymol. 2013;521:91-108 PMID: 23351735
  40. Critical role of the central 139-loop in stability and binding selectivity of arrestin-1.
    J Biol Chem. 2013 Apr 26;288(17):11741-50 PMID: 23476014
  41. Crystal structure of pre-activated arrestin p44.
    Nature. 2013 May 2;497(7447):142-6 PMID: 23604253
  42. Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide.
    Nature. 2013 May 2;497(7447):137-41 PMID: 23604254
  43. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data.
    J Comput Chem. 2013 Sep 30;34(25):2135-45 PMID: 23832629
  44. Biased ligands at G-protein-coupled receptors: promise and progress.
    Trends Pharmacol Sci. 2014 Jul;35(7):308-16 PMID: 24878326
  45. All-atom empirical potential for molecular modeling and dynamics studies of proteins.
    J Phys Chem B. 1998 Apr 30;102(18):3586-616 PMID: 24889800
  46. Generic GPCR residue numbers - aligning topology maps while minding the gaps.
    Trends Pharmacol Sci. 2015 Jan;36(1):22-31 PMID: 25541108
  47. SIGNAL TRANSDUCTION. Structural basis for nucleotide exchange in heterotrimeric G proteins.
    Science. 2015 Jun 19;348(6241):1361-5 PMID: 26089515
  48. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser.
    Nature. 2015 Jul 30;523(7562):561-7 PMID: 26200343
  49. Phospho-selective mechanisms of arrestin conformations and functions revealed by unnatural amino acid incorporation and (19)F-NMR.
    Nat Commun. 2015 Sep 08;6:8202 PMID: 26347956
  50. Long-Time-Step Molecular Dynamics through Hydrogen Mass Repartitioning.
    J Chem Theory Comput. 2015 Apr 14;11(4):1864-74 PMID: 26574392
  51. PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data.
    J Chem Theory Comput. 2013 Jul 9;9(7):3084-95 PMID: 26583988
  52. Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald.
    J Chem Theory Comput. 2013 Sep 10;9(9):3878-88 PMID: 26592383
  53. β-Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation.
    Nat Cell Biol. 2016 Mar;18(3):303-10 PMID: 26829388
  54. The conformational signature of β-arrestin2 predicts its trafficking and signalling functions.
    Nature. 2016 Mar 31;531(7596):665-8 PMID: 27007854
  55. β-Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle.
    Nature. 2016 Mar 31;531(7596):661-4 PMID: 27007855
  56. Kinetics, binding constant, and activation energy of the 48-kDa protein-rhodopsin complex by extra-metarhodopsin II.
    Biochemistry. 1989 Feb 21;28(4):1770-5 PMID: 2719933
  57. Understanding the Differential Selectivity of Arrestins toward the Phosphorylation State of the Receptor.
    ACS Chem Neurosci. 2016 Sep 21;7(9):1212-24 PMID: 27405242
  58. GPCR-G Protein-β-Arrestin Super-Complex Mediates Sustained G Protein Signaling.
    Cell. 2016 Aug 11;166(4):907-919 PMID: 27499021
  59. Functional competence of a partially engaged GPCR-β-arrestin complex.
    Nat Commun. 2016 Nov 09;7:13416 PMID: 27827372
  60. C-edge loops of arrestin function as a membrane anchor.
    Nat Commun. 2017 Feb 21;8:14258 PMID: 28220785
  61. Distinct conformations of GPCR-β-arrestin complexes mediate desensitization, signaling, and endocytosis.
    Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):2562-2567 PMID: 28223524
  62. Core engagement with β-arrestin is dispensable for agonist-induced vasopressin receptor endocytosis and ERK activation.
    Mol Biol Cell. 2017 Apr 15;28(8):1003-1010 PMID: 28228552
  63. Removal of phosphorylation sites from the beta 2-adrenergic receptor delays onset of agonist-promoted desensitization.
    Nature. 1988 May 26;333(6171):370-3 PMID: 2836733
  64. Muscarinic receptor regulates extracellular signal regulated kinase by two modes of arrestin binding.
    Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):E5579-E5588 PMID: 28652372
  65. Identification of Phosphorylation Codes for Arrestin Recruitment by G Protein-Coupled Receptors.
    Cell. 2017 Jul 27;170(3):457-469.e13 PMID: 28753425
  66. Structural basis of arrestin-3 activation and signaling.
    Nat Commun. 2017 Nov 10;8(1):1427 PMID: 29127291
  67. Catalytic activation of β-arrestin by GPCRs.
    Nature. 2018 May;557(7705):381-386 PMID: 29720660
  68. Topographic study of arrestin using differential chemical modifications and hydrogen/deuterium exchange.
    Protein Sci. 1994 Dec;3(12):2428-34 PMID: 7756996
  69. Visual arrestin interaction with rhodopsin. Sequential multisite binding ensures strict selectivity toward light-activated phosphorylated rhodopsin.
    J Biol Chem. 1993 Jun 5;268(16):11628-38 PMID: 8505295
  70. VMD: visual molecular dynamics.
    J Mol Graph. 1996 Feb;14(1):33-8, 27-8 PMID: 8744570
  71. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor.
    Nature. 1996 Oct 3;383(6599):447-50 PMID: 8837779
  72. Mechanism of phosphorylation-recognition by visual arrestin and the transition of arrestin into a high affinity binding state.
    Mol Pharmacol. 1997 Jan;51(1):161-9 PMID: 9016359
  73. Functional differences in the interaction of arrestin and its splice variant, p44, with rhodopsin.
    Biochemistry. 1997 Jul 29;36(30):9253-60 PMID: 9230059
Article Info
Journal
Nature
Abbr.
Nature
ISSN
1476-4687
Published
2018-00-00
Epub
2018-00-02
Pages
452-456
Language
English
Region
England
NLM ID
0410462
PMCID
PMC6294333
Subset
IM
Grants
NIH HHS · T15-LM007033-33 · United States
NIGMS NIH HHS · T32 GM008294 · United States
NIGMS NIH HHS · R01 GM127359 · United States
NLM NIH HHS · T15 LM007033 · United States
NIGMS NIH HHS · R01 GM116961 · United States
Corrections
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com